UPDATE: RBC Capital Upgrades Seagen (SGEN) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Seagen (SGEN) PT Lowered to $194 at Guggenheim
August 15, 2022 7:53 AM EDTGuggenheim analyst Michael Schmidt lowered the price target on Seagen (NASDAQ: SGEN) to $194.00 (from $204.00) while maintaining a Buy rating.... More
Seagen loses arbitration against Daiichi Sankyo over drug technology
August 12, 2022 1:39 PM EDT(Reuters) -U.S. drugmaker Seagen Inc said on Friday an arbitrator had ruled in favor of Japan's Daiichi Sankyo over an agreement between the two companies for using its drug technology.
The companies have been locked in a legal battle over patents on Daiichi and AstraZeneca Plc's breast-cancer... More
Seagen (SGEN) Issues Statement on Outcome of Daiichi Sankyo Arbitration, Says "Disappointed"
August 12, 2022 1:14 PM EDT(Updated - August 12, 2022 1:15 PM EDT)
Seagen Inc. (Nasdaq: SGEN) today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. (Daiichi Sankyo) relating to the parties 2008 collaboration agreement for the use of Seagens antibody-drug conjugate (ADC) technology. The... More
